A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
15
08
2023
accepted:
11
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
The continued emergence of highly pathogenic viruses, which either thwart immune- and small molecule-based therapies or lack interventions entirely, mandates alternative approaches, particularly for prompt and facile pre- and post-exposure prophylaxis. Many highly pathogenic viruses, including coronaviruses, employ the six-helix bundle heptad repeat membrane fusion mechanism to achieve infection. Although heptad-repeat-2 decoys can inhibit viral entry by blocking six-helix bundle assembly, the biophysical and pharmacologic liabilities of peptides have hindered their clinical development. Here, we develop a chemically stapled lipopeptide inhibitor of SARS-CoV-2 as proof-of-concept for the platform. We show that our lead compound blocks infection by a spectrum of SARS-CoV-2 variants, exhibits mucosal persistence upon nasal administration, demonstrates enhanced stability compared to prior analogs, and mitigates infection in hamsters. We further demonstrate that our stapled lipopeptide platform yields nanomolar inhibitors of respiratory syncytial, Ebola, and Nipah viruses by targeting heptad-repeat-1 domains, which exhibit strikingly low mutation rates, enabling on-demand therapeutic intervention to combat viral outbreaks.
Identifiants
pubmed: 38177138
doi: 10.1038/s41467-023-44361-1
pii: 10.1038/s41467-023-44361-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
274Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. COVID-19 Dashboard (WHO, 2023).
Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263–273 (1997).
doi: 10.1016/S0092-8674(00)80205-6
pubmed: 9108481
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426–430 (1997).
doi: 10.1038/387426a0
pubmed: 9163431
Zhao, X., Singh, M., Malashkevich, V. N. & Kim, P. S. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl Acad. Sci. USA 97, 14172–14177 (2000).
doi: 10.1073/pnas.260499197
pubmed: 11106388
pmcid: 18890
Bullough, P. A., Hughson, F. M., Skehel, J. J. & Wiley, D. C. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371, 37–43 (1994).
doi: 10.1038/371037a0
pubmed: 8072525
Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289, 366–373 (1981).
doi: 10.1038/289366a0
pubmed: 7464906
Malashkevich, V. N. et al. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc. Natl Acad. Sci. USA 96, 2662–2667 (1999).
doi: 10.1073/pnas.96.6.2662
pubmed: 10077567
pmcid: 15825
Weissenhorn, W., Carfí, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605–616 (1998).
doi: 10.1016/S1097-2765(00)80159-8
pubmed: 9844633
Harrison, J. S., Koellhoffer, J. F., Chandran, K. & Lai, J. R. Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain alpha-helical bundle. Biochemistry 51, 2515–2525 (2012).
doi: 10.1021/bi3000353
pubmed: 22369502
Lou, Z. et al. Crystal structures of Nipah and Hendra virus fusion core proteins. FEBS J. 273, 4538–4547 (2006).
doi: 10.1111/j.1742-4658.2006.05459.x
pubmed: 16972940
pmcid: 7164058
Xu, Y. et al. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J. Biol. Chem. 279, 49414–49419 (2004).
doi: 10.1074/jbc.M408782200
pubmed: 15345712
Chan, D. C., Chutkowski, C. T. & Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl Acad. Sci. USA 95, 15613–15617 (1998).
doi: 10.1073/pnas.95.26.15613
pubmed: 9861018
pmcid: 28092
Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302–1307 (1998).
doi: 10.1038/3293
pubmed: 9809555
Lu, L. et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014).
doi: 10.1038/ncomms4067
pubmed: 24473083
Xia, S. et al. Potent MERS-CoV fusion inhibitory peptides identified from HR2 domain in spike protein of bat coronavirus HKU4. Viruses 11, 56 (2019).
Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343–355 (2020).
doi: 10.1038/s41422-020-0305-x
pubmed: 32231345
pmcid: 7104723
Xia, S. et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 5, eaav4580 (2019).
doi: 10.1126/sciadv.aav4580
pubmed: 30989115
pmcid: 6457931
Bird, G. H. et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc. Natl Acad. Sci. USA 107, 14093–14098 (2010).
doi: 10.1073/pnas.1002713107
pubmed: 20660316
pmcid: 2922607
Bird, G. H. et al. Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. J. Clin. Invest. 124, 2113–2124 (2014).
doi: 10.1172/JCI71856
pubmed: 24743147
pmcid: 4001541
de Vries, R. D. et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 371, 1379–1382 (2021).
doi: 10.1126/science.abf4896
pubmed: 33597220
pmcid: 8011693
Efaz, F. M. et al. Repurposing fusion inhibitor peptide against SARS-CoV-2. J Comput Chem (2021).
Yu, D. et al. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg. Microbes Infect. 10, 1227–1240 (2021).
doi: 10.1080/22221751.2021.1937329
pubmed: 34057039
pmcid: 8216258
Zhou, J. et al. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm. Sin. B 12, 1652–1661 (2022).
doi: 10.1016/j.apsb.2021.07.026
pubmed: 34367893
Zhu, Y. et al. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. Emerg. Microbes Infect. 11, 1819–1827 (2022).
doi: 10.1080/22221751.2022.2098060
pubmed: 35786417
pmcid: 9310806
Zhu, Y., Hu, Y., Liu, N., Chong, H. & He, Y. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides. Antivir. Res. 208, 105445 (2022).
doi: 10.1016/j.antiviral.2022.105445
pubmed: 36265805
Zhu, Y., Yu, D., Yan, H., Chong, H. & He, Y. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol 94, e00635–20 (2020).
Ingallinella, P. et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl Acad. Sci. USA 106, 5801–5806 (2009).
doi: 10.1073/pnas.0901007106
pubmed: 19297617
pmcid: 2667053
Bridges, J. P., Vladar, E. K., Huang, H. & Mason, R. J. Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Thorax 77, 203–209 (2022).
doi: 10.1136/thoraxjnl-2021-217561
pubmed: 34404754
Matthews, T. et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3, 215–225 (2004).
doi: 10.1038/nrd1331
pubmed: 15031735
Monteiro, A., Yu, K. O. A. & Hicar, M. D. Peptide-based fusion inhibitors for preventing the six-helix bundle formation of class I fusion proteins: HIV and beyond. Curr. HIV Res. 19, 465–475 (2021).
doi: 10.2174/1570162X19666210908115231
pubmed: 34503415
pmcid: 9166635
Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924–944 (2022).
doi: 10.1016/S0140-6736(22)00152-0
pubmed: 35202601
pmcid: 8863502
Abbasian, M. H. et al. Global landscape of SARS-CoV-2 mutations and conserved regions. J. Transl. Med. 21, 152 (2023).
doi: 10.1186/s12967-023-03996-w
pubmed: 36841805
pmcid: 9958328
Lamers, C. Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discov. 4, FDD75 (2022).
doi: 10.4155/fdd-2022-0005
Walensky, L. D. & Bird, G. H. Hydrocarbon-stapled peptides: principles, practice, and progress. J. Med. Chem. 57, 6275–6288 (2014).
doi: 10.1021/jm4011675
pubmed: 24601557
pmcid: 4136684
Wang, L. et al. Therapeutic peptides: current applications and future directions. Signal Transduct. Target Ther. 7, 48 (2022).
doi: 10.1038/s41392-022-00904-4
pubmed: 35165272
pmcid: 8844085
Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58, 7370–7380 (2015).
doi: 10.1021/acs.jmedchem.5b00726
pubmed: 26308095
Bird, G. H. et al. Hydrocarbon-stitched peptide agonists of glucagon-like peptide-1 receptor. ACS Chem. Biol. 15, 1340–1348 (2020).
doi: 10.1021/acschembio.0c00308
pubmed: 32348108
pmcid: 7366314
Saleh, M. N. et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin. Cancer Res. 27, 5236–5247 (2021).
doi: 10.1158/1078-0432.CCR-21-0715
pubmed: 34301750
pmcid: 9401461
Patten, J. J. et al. Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization. iScience 25, 104925 (2022).
doi: 10.1016/j.isci.2022.104925
pubmed: 35992305
pmcid: 9374494
Root, M. J., Kay, M. S. & Kim, P. S. Protein design of an HIV-1 entry inhibitor. Science 291, 884–888 (2001).
doi: 10.1126/science.1057453
pubmed: 11229405
Danial, N. N. et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat. Med. 14, 144–153 (2008).
doi: 10.1038/nm1717
pubmed: 18223655
pmcid: 3918232